Company intelligence / Profile preview

Sagesse Bio

unknown, Delaware, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Sagesse Bio’s lead compound, SGY‑101, is an siRNA-based therapeutic targeting TGF‑β1 and COX‑2 for localized fat reduction. The drug is IND-enabled and currently in Phase II clinical trials for other indications. Early human studies have shown good tolerability with evidence of adipocytolysis. The company aims to address unmet needs in noninvasive body contouring and tissue remodeling within aesthetic medicine

Therapeutic areas: Dermatology
Modalities: Small interfering RNARNAi-based drugsNanoparticle (histidine-lysine nanoparticle delivery)
Industry: Biotech

Drug pipeline

1 asset

SGY-101

Preclinical

Partnerships

Sirnaomics Ltd.Gore Range Capital LLC

Beyond the preview

Go deeper on Sagesse Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sagesse Bio.

Explore the full profile